DAX-0,37 % EUR/USD+0,03 % Gold-0,08 % Öl (Brent)0,00 %

ANALYSE: Akorn-Aktie möglicherweise vor noch größerem Absturz - Raymond James (Seite 6) | Diskussion im Forum

Begriffe und/oder Benutzer


Hmmm...oder aber Szenario 2,5: das ganze zieht sich noch etwas hin...*grummel*
könnte aber für Szenario 3 sprechen...also keine schwarz oder weiß Entscheidung sondern ein Abschlag vom Ursprungspreis in Höhe der Kosten einer Überarbeitung der Betriebsprozesse bei Akorn (ca. 200-300 Millionen $)...wäre immer noch ein enormer Aufschlag zum jetzigen Kurs...:cool:
So geht es weiter:

The remaining timeline is as follows post the trial:

July 26 - Fresenius Opening Brief
August 6 - AKRX Response
August 13 - Fresenius Counterclaim
August 20 - AKRX Counterclaim
August 23 - Post-Trial Argument

AKRX wanted a much longer post-trial brief period suggesting that ARKX believes the following:

1. Good news from the FDA (maybe an ANDA approval?)
2. No news from the FDA coming soon (no facility shutdown?/warning letter?)

Quelle: Seeking Alpha

Die Royal Bank of Canada sieht die Chancen für eine Gerichtsentscheidung zu Gunsten von Akorn mittlerweile bei 70% und hat das Kursziel auf 27$ angehoben...es bleibt also spannend! :cool:
-16% -- Akorn falls after judge says he has more to do before decision

Shares of Akorn (AKRX) are falling after Judge Delaware Chancery Court Judge Travis Laster said he has more to do before making a decision on the company's case against Fresenius (FSNUY).

The latter is seeking to cancel its proposed acquisition of Akorn at $34 per share. "I've got a lot to do before I decide this case," Laster said during a hearing today, according to Bloomberg.

The news agency also cited Fresenius lawyer Lewis Clayton as telling Laster that his company has a "powerful case" that Akorn violated the merger agreement. Shares of Akorn are down 10%, or $1.85, to $16.26 in midday trading.
Antwort auf Beitrag Nr.: 58.521.570 von faultcode am 23.08.18 21:31:13
No Clear Winner In .3B Akorn Deal Row: Vice Chancellor

Law360 (August 23, 2018, 8:24 PM EDT) -- A Delaware vice chancellor warned Thursday that he saw no obvious winner in a battle over Fresenius Kabi AG’s bid to walk away from a $4.3 billion deal to buy generic-drug maker Akorn Inc., with both sides accusing the other of fatal breaches during post-trial arguments.

In the case, now submitted for a ruling, an attorney for Akorn argued that “buyer’s remorse” motivated Fresenius to declare a termination of the tie-up on April 22, before the deal had closed...
Dem Einbruch der Akorn Aktien zufolge scheint der Richter ein paar kritische Fragen ggüber Akorn aufgeworfen zu haben.
Judge says Fresenius can walk away from $4.8 bln Akorn deal --> -47% premarket

A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

Delaware Vice Chancellor Travis Laster said Fresenius validly terminated the merger agreement and he found Akorn's representations regarding its compliance with regulatory requirements were "not true and correct."

Shares of Akorn plunged 47 percent in premarket U.S. trading, while shares of Fresenius jumped 7.5 percent.

Akorn did not immediately respond to a request for comment.

Laster, who oversaw a five-day trial, wrote in a 246-page opinion that Akorn's "magnitude of inaccuracies would reasonably be expected to result in a material adverse effect," allowing Fresenius to walk away.

Laster also said Akorn breached its obligation to continue operating in the ordinary course after signing the deal.

The judge has said he anticipates one or both sides would appeal his opinion to the state's Supreme Court...
Antwort auf Beitrag Nr.: 58.842.870 von faultcode am 01.10.18 15:23:59Aktienkurs nähert sich damit langsam dem Buchwert an bei so USD5.75 per 30.6.2018
Antwort auf Beitrag Nr.: 58.842.924 von faultcode am 01.10.18 15:29:59
AKRX: intention to appeal
Akorn Offers Comment On Delaware Complaint Against Fresenius
9:26 am ET October 1, 2018 (Benzinga) Print

“We are disappointed by the ruling by the Delaware Chancery Court determining not to force Fresenius to close and we continue to believe Fresenius’ attempt to terminate the transaction is in breach of our binding merger agreement.

We intend to appeal, in an effort to vigorously enforce our rights and continue to protect the interests of our Company and our shareholders.”

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fresenius muss Akorn nicht übernehmen

Beitrag zu dieser Diskussion schreiben